NCT06597500View on ClinicalTrials.gov

A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

December 16, 2024

Study Completion Date

December 23, 2024

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK3923868

GSK3923868 will be administered.

DRUG

Itraconazole

Itraconazole will be administered.

Trial Locations (1)

CB2 0GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT06597500 - A Study to Evaluate the Effect of Itraconazole on the Concentration of GSK3923868 in the Blood in Healthy Participants | Biotech Hunter | Biotech Hunter